Movement Alert｜Liquidia Technologies Inc rises 5.06% in Pre-Market Trading, analyst target increases add to post-earnings momentum

Market Focus11-11

On November 11, Liquidia Technologies Inc rose 5.06% in Pre-Market Trading, trading at $54.0 per share, with turnover of $1.3833 million.

The latest identified catalyst was a wave of analyst follow-through after the company’s third-quarter results, including a price target increase from BofA to $54 from $42, a target increase from Needham to $66 from $58, and BTIG reiterating Buy with an $87 target.

That reassessment came after Liquidia reported third-quarter revenue of $225.3 million, above the $214.2 million consensus, with YUTREPIA net product sales of $222.7 million and October patient shipments reaching a monthly high. Although the company posted a loss of $2.64 per share due largely to a roughly $389.7 million litigation settlement charge tied to United Therapeutics, the recent market focus has centered on stronger core commercial execution and reduced uncertainty following the settlement.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment